The failure of anti-IL-5 therapies, which while successful in reducing eosinophilia had no impact on COPD exacerbation rate in most individual studies, further weakens the concept of eosinophilia as an important contributor to the morbidity of COPD. The gene discussed is IL5; the disease is Increased total eosinophil count.